2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T5ab1,

Summary Table

Category	Details
Risk Factors	Advanced maternal age (primary); advanced paternal age (minor contribution)
Etiology	Meiotic nondisjunction producing a 47,XXY karyotype (most common); variants include 48,XXXY, 48,XXYY, 49,XXXXY, and mosaic 46,XY/47,XXY
Patient Presentation	Adolescent or adult male with delayed puberty, tall stature with long lower extremities, gynecomastia, small firm testes, and primary infertility (azoospermia). Often mild learning or language delays in childhood.
Classic Physical Exam	Tall, eunuchoid body habitus (arm span exceeds height; lower segment longer than upper); bilateral small, firm testes ($< 6$ mL or $< 2.5$ cm); sparse facial/body hair; gynecomastia; decreased muscle mass
Key Diagnostic Results	Hypergonadotropic hypogonadism: $\uparrow$ FSH, $\uparrow$ LH, $\downarrow$ testosterone, $\uparrow$ estradiol-to-testosterone ratio; semen analysis shows azoospermia. Karyotype confirms 47,XXY.
Management	Testosterone replacement therapy starting at puberty; assisted reproduction via testicular sperm extraction (TESE) with intracytoplasmic sperm injection (ICSI); speech therapy and educational support; screening for metabolic and bone disease
Keywords	"Tall adolescent boy with small firm testes," "gynecomastia and infertility," "47,XXY," "primary hypogonadism with azoospermia," "eunuchoid proportions," "long legs disproportionate to trunk"

1. Pathophysiology

Klinefelter syndrome results from meiotic nondisjunction during gametogenesis, leaving the male zygote with at least one extra X chromosome. The most common karyotype is 47,XXY, accounting for roughly 80 to 90 percent of cases. Nondisjunction is maternal in origin in about half of cases, explaining the link with advanced maternal age. The remaining cases arise from paternal nondisjunction or post-zygotic mitotic errors that produce mosaic forms (46,XY/47,XXY), which often have a milder phenotype.

The extra X chromosome causes progressive seminiferous tubule hyalinization and fibrosis, beginning in mid-puberty. Sertoli and Leydig cell function declines, leading to azoospermia and androgen deficiency. Because the gonads fail at the level of the testis, the pituitary loses negative feedback, and FSH and LH rise dramatically. This is the textbook picture of primary (hypergonadotropic) hypogonadism.

Androgen deficiency during puberty explains the clinical phenotype. Without adequate testosterone, epiphyseal plates remain open longer, producing disproportionately long lower extremities and the eunuchoid habitus (arm span greater than height by more than 2 cm; lower body segment longer than upper). Reduced androgen action also causes sparse facial and pubic hair, decreased muscle bulk, and small phallus development. The relative excess of estrogen, generated by peripheral aromatization of weak androgens combined with Leydig cell dysfunction, drives gynecomastia.

The supernumerary X also contributes to neurocognitive features. Genes that escape X-inactivation (in the pseudoautosomal regions) produce a gene-dosage effect, which is linked to mild language-based learning difficulties, reduced verbal IQ, and increased rates of attention problems. Importantly, the great majority of affected men have normal intelligence.

A clinically important consequence is the elevated lifetime risk of breast cancer (roughly 20 to 50 times that of the general male population), mediastinal germ cell tumors, osteoporosis, metabolic syndrome, and autoimmune disease, all linked to the abnormal hormonal milieu and chromosomal background.

2. Classification and Clinical Manifestations

Karyotype / Variant	Frequency	Clinical Severity
47,XXY (classic)	~80 to 90%	Standard phenotype: tall stature, small testes, gynecomastia, azoospermia
46,XY / 47,XXY (mosaic)	~10%	Milder; some patients retain partial spermatogenesis and fertility
48,XXYY	Rare	Taller, more behavioral and cognitive impairment, peripheral vascular disease
48,XXXY	Rare	More pronounced cognitive delay, dysmorphic features
49,XXXXY	Very rare	Severe cognitive impairment, congenital heart disease, skeletal abnormalities, hypogenitalism

Life Stage	Clinical Manifestations
Prenatal / Infancy	Often clinically silent; sometimes detected on noninvasive prenatal screening or amniocentesis. Mild hypotonia and cryptorchidism in some
Childhood	Mild speech and language delay, reading difficulty, shy or withdrawn temperament; growth normal or accelerated
Adolescence	Onset of puberty may begin normally but fails to progress; testes remain small, gynecomastia appears, growth spurt produces long legs
Adulthood	Infertility (often the presenting complaint), low libido, erectile dysfunction, fatigue, decreased muscle and bone mass, metabolic syndrome, depression

3. Diagnostic Workup

Test	Purpose	Expected Finding
Serum FSH, LH, total testosterone	Best initial screening test	$\uparrow$ FSH, $\uparrow$ LH, $\downarrow$ or low-normal testosterone
Semen analysis	Evaluate fertility	Azoospermia (occasionally severe oligospermia in mosaics)
Karyotype (peripheral blood lymphocytes)	Confirmatory / Gold standard	47,XXY (or variant)
Estradiol, SHBG	Supportive	$\uparrow$ estradiol; $\uparrow$ SHBG; high estradiol-to-testosterone ratio
DEXA scan	Screen for osteopenia / osteoporosis	Reduced bone mineral density
Fasting glucose, lipid panel, HbA1c	Screen for metabolic syndrome	May show insulin resistance, dyslipidemia
Breast exam $\pm$ imaging	Surveillance for breast cancer	Persistent or asymmetric gynecomastia warrants imaging

The workup begins when a clinician encounters a tall adolescent or young man with small firm testes, gynecomastia, or unexplained infertility. The best initial step is a hormonal panel measuring FSH, LH, and total testosterone in the early morning. The hallmark biochemical pattern is primary hypogonadism: markedly elevated gonadotropins with low or low-normal testosterone. Semen analysis typically reveals azoospermia, which is the most common reason for adult diagnosis (the condition is identified during a fertility workup in a substantial fraction of cases).

The most accurate, confirmatory test is the peripheral blood karyotype, demonstrating 47,XXY. If mosaicism is suspected and the standard karyotype is negative despite a strong clinical picture, additional cells should be analyzed, or fluorescence in situ hybridization (FISH) on buccal mucosa or skin fibroblasts can be used.

After diagnosis, baseline assessment should include a DEXA scan, fasting glucose and lipid profile, thyroid function tests, and a clinical breast examination. Imaging is reserved for asymmetric or rapidly enlarging breast tissue, given the elevated breast cancer risk. Mediastinal imaging is not routine but should be pursued if symptoms suggest a germ cell tumor.

4. Management and Treatment

Component	Intervention	Notes
Androgen replacement	Testosterone (intramuscular, transdermal gel/patch, or long-acting injectable)	Start at puberty (around 11 to 12 years) or at diagnosis; titrate to mid-normal adult range
Fertility	Testicular sperm extraction (TESE or microTESE) with ICSI	Best yield when performed earlier in adulthood, before further tubular fibrosis
Gynecomastia	Reduction mammoplasty if persistent or distressing	Testosterone alone rarely reverses established gynecomastia
Bone health	Calcium, vitamin D, weight-bearing exercise, bisphosphonates if osteoporosis	Driven by chronic hypogonadism
Metabolic and cardiovascular	Lifestyle counseling, screening, treat dyslipidemia and diabetes	Higher baseline cardiometabolic risk
Neurodevelopmental	Speech therapy, individualized education, psychological support	Address early in childhood when diagnosed prenatally or in infancy
Surveillance	Annual breast exam, periodic DEXA, fasting metabolic panel	Vigilance for breast cancer and germ cell tumors

Management hinges on testosterone replacement therapy (TRT), ideally initiated at the start of puberty when biochemical hypogonadism becomes apparent, or at diagnosis in adults with low testosterone. Common regimens include testosterone cypionate or enanthate 50 to 100 mg intramuscularly every 1 to 2 weeks in adolescents, increasing to adult doses of 100 to 200 mg every 1 to 2 weeks, or transdermal preparations dosed daily. Long-acting injectable testosterone undecanoate ($1000$ mg every 10 to 14 weeks after loading) is also used. The aim is to restore secondary sexual characteristics, support bone density and muscle mass, and improve mood, libido, and metabolic parameters.

TRT should be monitored every 3 to 6 months initially with serum testosterone (target mid-normal range), hematocrit, prostate-specific antigen in older patients, and lipid profile. Contraindications include known prostate or breast cancer, untreated severe sleep apnea, erythrocytosis (hematocrit $> 54%$), and uncontrolled heart failure. Importantly, testosterone therapy does not restore fertility; in fact, exogenous testosterone suppresses any residual spermatogenesis, so men who wish to father children should pursue sperm retrieval before starting TRT or after a washout period.

For fertility, the standard approach is microdissection testicular sperm extraction (microTESE) combined with ICSI, which retrieves sperm in roughly 40 to 50 percent of patients. Outcomes are better when performed in younger men, since seminiferous tubule fibrosis worsens with age. Counseling should address the option of donor sperm or adoption.

The next best step when an adolescent presents with the classic phenotype and laboratory findings consistent with primary hypogonadism is to order a karyotype before initiating long-term testosterone, both to confirm the diagnosis and to provide accurate genetic counseling.

Long-term care includes lifestyle interventions for metabolic syndrome, bone density monitoring, annual breast examination, and psychosocial support for issues including depression, social anxiety, and reduced quality of life that can accompany the diagnosis.

5. Differential Diagnosis and Distractors

Differential Diagnosis	Why It's Similar	Key Discriminator
Kallmann syndrome	Delayed puberty, infertility, eunuchoid body proportions	Hypogonadotropic hypogonadism (low FSH, low LH); often anosmia; karyotype 46,XY
Constitutional delay of puberty	Tall final height after delayed pubertal onset	Eventually undergoes full spontaneous puberty; normal testes size and karyotype; gonadotropins eventually normalize
Marfan syndrome	Tall, long-limbed, eunuchoid habitus	Normal testes and fertility; aortic root dilation, lens dislocation, joint hypermobility; FBN1 mutation
Androgen insensitivity syndrome (complete)	Tall stature, sparse body hair, infertility	46,XY phenotypic female with absent uterus and intra-abdominal testes; raised as female
Primary testicular failure (acquired)	Hypergonadotropic hypogonadism with small testes	History of mumps orchitis, chemotherapy, radiation, or trauma; testes typically soft rather than firm; karyotype 46,XY
Fragile X syndrome	Tall stature, learning difficulty, large testes (post-puberty)	Macroorchidism rather than small testes; long face, large ears; FMR1 CGG triplet expansion
XYY syndrome (47,XYY)	Tall stature, sometimes learning difficulties	Normal testes, normal fertility, normal testosterone; no gynecomastia
Prader-Willi syndrome	Hypogonadism, infertility	Hyperphagia and obesity, hypotonia in infancy, short stature, intellectual disability; chromosome 15q11 deletion

6. Traps and High-Yield Pearls

The most common way students get this question wrong is by anchoring on tall stature alone and choosing Marfan syndrome, or by missing the diagnosis when the vignette emphasizes infertility in an otherwise healthy adult man. The decisive feature is the combination of small, firm testes with elevated FSH and LH and low testosterone. Whenever you see a tall adolescent or young man with gynecomastia plus disproportionately small testes, the test writer is steering you toward Klinefelter syndrome, even if intellectual function is described as normal.

A second common trap is confusing primary versus secondary hypogonadism. Klinefelter is a primary (hypergonadotropic) hypogonadism, so gonadotropins are high. If FSH and LH are low, the answer is hypothalamic-pituitary disease, often Kallmann syndrome. Another classic distractor is fragile X, which also presents with tall stature and learning difficulty but features macroorchidism, the opposite of Klinefelter.

Remember that karyotype is the gold standard, not hormone testing. Hormones support the diagnosis but cannot confirm the chromosomal abnormality. Also remember that testosterone therapy does not treat infertility and will worsen it; sperm retrieval should be considered before TRT in men who want biological children.

The core competencies being tested are: recognizing the classic phenotype (tall, small firm testes, gynecomastia, infertility), interpreting the hormonal pattern of primary hypogonadism, selecting karyotype as the confirmatory test, counseling about lifelong testosterone replacement and its effect on fertility, and maintaining surveillance for the associated comorbidities, particularly breast cancer, osteoporosis, metabolic syndrome, and mediastinal germ cell tumors.

1e:["$","$L2d",null,{"article":{"id":"cb9b6b25-c18c-4708-9287-68e03412273d","title":"Sindrom Klinefelter","content":"$2e","category":"Endokrin-Metabolik","created_at":"2026-05-06T07:41:14.320947+00:00","status":"published","subcategory":null},"questionCount":2,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestations","num":"02","title":"Classification and Clinical Manifestations"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]